CLINICAL TRIALS PROFILE FOR HYDROXYPROGESTERONE CAPROATE
✉ Email this page to a colleague
All Clinical Trials for HYDROXYPROGESTERONE CAPROATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00099164 ↗ | Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS) | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 3 | 2004-04-01 | Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets. |
| NCT00099164 ↗ | Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS) | Completed | The George Washington University Biostatistics Center | Phase 3 | 2004-04-01 | Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets. |
| NCT00120640 ↗ | Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate | Withdrawn | Yale University | N/A | 2005-07-01 | The goal of our research will be to determine the effectiveness of 17 alpha-hydroxyprogesterone caproate (17P) in the treatment of preterm delivery. Treatment with progesterone is emerging as the standard of care for prevention of preterm delivery in asymptomatic patients at high risk for preterm birth due to a prior preterm delivery. Our goal is to evaluate whether or not progesterone is also effective in reducing preterm birth in symptomatic patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for HYDROXYPROGESTERONE CAPROATE
Condition Name
Clinical Trial Locations for HYDROXYPROGESTERONE CAPROATE
Trials by Country
Clinical Trial Progress for HYDROXYPROGESTERONE CAPROATE
Clinical Trial Phase
Clinical Trial Sponsors for HYDROXYPROGESTERONE CAPROATE
Sponsor Name
| Sponsor Name for HYDROXYPROGESTERONE CAPROATE | |
| Sponsor | Trials |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 7 |
| AMAG Pharmaceuticals, Inc. | 6 |
| The George Washington University Biostatistics Center | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
